Michael Vajdy
Overview
Explore the profile of Michael Vajdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yu M, Goodsell A, Zhou F, Vajdy M
Immunol Lett
. 2011 Mar;
138(1):63-70.
PMID: 21421009
To determine whether long-term immunological B cell memory following mucosal vaccinations is maintained by terminally differentiated Ig-CD45R- plasma cells or Ig+CD45R+ B cells, we immunized mice orally with the non-toxic...
12.
Yu M, Vajdy M
Vaccine
. 2011 Jan;
29(13):2429-36.
PMID: 21272602
Non-replicating protein- or DNA-based antigens generally require immune-enhancing adjuvants and delivery systems. It has been particularly difficult to raise antibodies against gp120 of HIV-1, which constitutes an important approach in...
13.
Yu M, Vajdy M
Expert Opin Biol Ther
. 2010 Jul;
10(8):1181-95.
PMID: 20624114
Importance Of The Field: There are currently over thirty million people infected with HIV and there are no vaccines available to prevent HIV infections or disease. The genitourinary, rectal and...
14.
Barnett S, Burke B, Sun Y, Kan E, Legg H, Lian Y, et al.
J Virol
. 2010 Apr;
84(12):5975-85.
PMID: 20392857
We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIV(SF162P4) following sequential immunization with alphavirus replicon particles (VRP) of a chimeric...
15.
Zhou F, Goodsell A, Uematsu Y, Vajdy M
Clin Vaccine Immunol
. 2009 Feb;
16(4):471-8.
PMID: 19193829
Seasonal influenza virus infections cause considerable morbidity and mortality in the world, and there is a serious threat of a pandemic influenza with the potential to cause millions of deaths....
16.
Lin Y, Kwon T, Polo J, Zhu Y, Coates S, Crawford K, et al.
J Virol
. 2008 May;
82(15):7492-503.
PMID: 18508900
Broad, multispecific CD4(+) and CD8(+) T-cell responses to the hepatitis C virus (HCV), as well as virus-cross-neutralizing antibodies, are associated with recovery from acute infection and may also be associated...
17.
Srivastava I, Goodsell A, Zhou F, Sun Y, Burke B, Barnett S, et al.
Vaccine
. 2008 Apr;
26(22):2796-806.
PMID: 18440102
In this study, immunizations at 2 weeks vs. 6 weeks intervals, with an HIV-1 envelope protein in adjuvants, through intra-nasal (IN), intra-muscular (IM), IN followed by IM (IN/IM) and IM/IN,...
18.
Wendorf J, Chesko J, Kazzaz J, Ugozzoli M, Vajdy M, OHagan D, et al.
Hum Vaccin
. 2008 Apr;
4(1):44-9.
PMID: 18438105
The objective of this work was to conduct an in vivo comparison of nanoparticles and microparticles as vaccine delivery systems. Poly (lactide-co-glycolide) (PLG) polymers were used to create nanoparticles size...
19.
Barnett S, Srivastava I, Kan E, Zhou F, Goodsell A, Cristillo A, et al.
AIDS
. 2008 Jan;
22(3):339-48.
PMID: 18195560
Background: Worldwide, the majority of human immunodeficiency virus (HIV) infections occur by heterosexual transmission. Thus, the development of a vaccine that can prevent intravaginal HIV infection is an important goal...
20.
Rath B, Linder T, Cornblath D, Hudson M, Fernandopulle R, Hartmann K, et al.
Vaccine
. 2007 Nov;
26(1):1-14.
PMID: 18037542
Bell's palsy has been reported as an adverse event following immunization (AEFI). Review of the published literature reveals that several characteristics have been used to describe Bell's palsy, which differ...